Joel Drewry (HBSc 2008, PhD 2012)

Joel DrewryPresident and CEO, Jobs in Education

Prior to joining Blueline in 2014, Joel was an industrial post-doctoral fellow at the Centre for Probe Development and Commercialization. His research at the CPDC involved designing and developing a proprietary linker-payload platform that enables the efficient conversion of antibodies and other targeting vectors into radioimmunoconjugate therapeutics for oncology. The first radioimmunoconjugate developed at the CPDC completed phase I trials in 2014.

In addition to his role at Blueline, Joel serves as a Strategy and Operations Associate at Northern Biologics, an antibody therapeutics start-up financed by Versant and Celgene in 2014.

Joel received a PhD in organic chemistry from the University of Toronto in 2012, where he studied medicinal chemistry and molecular recognition.

Read more Boundless portraits or submit your story.

Find Us on FacebookFollow Us on TwitterJoin Us on LinkedIn

home | privacy | events